Zhong Jingyu, Hu Yangfan, Ge Xiang, Xing Yue, Ding Defang, Zhang Guangcheng, Zhang Huan, Yang Qingcheng, Yao Weiwu
Department of Imaging, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, No. 1111 Xianxia Road, Shanghai, 200336, China.
Department of Sports Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, No. 600 Yishan Road, Shanghai, 200233, China.
Eur Radiol. 2023 Feb;33(2):1433-1444. doi: 10.1007/s00330-022-09060-3. Epub 2022 Aug 26.
To evaluate the study quality and clinical value of radiomics studies on chondrosarcoma.
PubMed, Embase, Web of Science, China National Knowledge Infrastructure, and Wanfang Data were searched for articles on radiomics for evaluating chondrosarcoma as of January 31, 2022. The study quality was assessed according to Radiomics Quality Score (RQS), Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) checklist, Image Biomarker Standardization Initiative (IBSI) guideline, and modified Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool. The level of evidence supporting clinical use of radiomics on chondrosarcoma differential diagnosis was determined based on meta-analyses.
Twelve articles were included. The median RQS was 10.5 (range, -3 to 15), with an adherence rate of 36%. The adherence rate was extremely low in domains of high-level evidence (0%), open science and data (17%), and imaging and segmentation (35%). The adherence rate of the TRIPOD checklist was 61%, and low for section of title and abstract (13%), introduction (42%), and results (56%). The reporting rate of pre-processing steps according to the IBSI guideline was 60%. The risk of bias and concern of application were mainly related to the index test. The meta-analysis on differential diagnosis of enchondromas vs. chondrosarcomas showed a diagnostic odds ratio of 43.90 (95% confidential interval, 25.33-76.10), which was rated as weak evidence.
The current scientific and reporting quality of radiomics studies on chondrosarcoma was insufficient. Radiomics has potential in facilitating the optimization of operation decision-making in chondrosarcoma.
• Among radiomics studies on chondrosarcoma, although differential diagnostic models showed promising performance, only pieces of weak level of evidence were reached with insufficient study quality. • Since the RQS rating, the TRIPOD checklist, and the IBSI guideline have largely overlapped with each other, it is necessary to establish one widely acceptable methodological and reporting guideline for radiomics research. • The TRIPOD model typing, the phase classification of image mining studies, and the level of evidence category are useful tools to assess the gap between academic research and clinical application, although their modifications for radiomics studies are needed.
评估骨肉瘤的放射组学研究的质量及临床价值。
检索截至2022年1月31日PubMed、Embase、Web of Science、中国知网和万方数据中有关用于评估骨肉瘤的放射组学的文章。根据放射组学质量评分（RQS）、个体预后或诊断的多变量预测模型透明报告（TRIPOD）清单、图像生物标志物标准化倡议（IBSI）指南以及改良的诊断准确性研究质量评估（QUADAS-2）工具对研究质量进行评估。基于荟萃分析确定支持放射组学在骨肉瘤鉴别诊断中临床应用的证据水平。
纳入12篇文章。RQS中位数为10.5（范围：-3至15），依从率为36%。在高水平证据（0%）、开放科学和数据（17%）以及成像和分割（35%）领域，依从率极低。TRIPOD清单的依从率为61%，在标题和摘要部分（13%）、引言（42%）和结果（56%）部分较低。根据IBSI指南，预处理步骤的报告率为60%。偏倚风险和应用关注主要与指标试验有关。软骨瘤与骨肉瘤鉴别诊断的荟萃分析显示诊断比值比为43.90（95%置信区间，25.33 - 76.10），被评为弱证据。
目前骨肉瘤放射组学研究的科学性和报告质量不足。放射组学在促进骨肉瘤手术决策优化方面具有潜力。
• 在骨肉瘤的放射组学研究中，尽管鉴别诊断模型显示出有前景的性能，但研究质量不足，仅达到了弱证据水平。• 由于RQS评分、TRIPOD清单和IBSI指南在很大程度上相互重叠，因此有必要为放射组学研究建立一个广泛接受的方法学和报告指南。• 尽管需要对放射组学研究进行修改，但TRIPOD模型类型、图像挖掘研究的阶段分类以及证据水平类别是评估学术研究与临床应用之间差距的有用工具。
